176 related articles for article (PubMed ID: 38532425)
1. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer - a prospective multicenter study.
Rönningås U; Holm M; Fransson P; Beckman L; Wennman-Larsen A
BMC Palliat Care; 2024 Mar; 23(1):80. PubMed ID: 38532425
[TBL] [Abstract][Full Text] [Related]
2. The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
Kim VS; Yang H; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen AR; Tomlinson G; Alibhai SMH
J Geriatr Oncol; 2023 Mar; 14(2):101417. PubMed ID: 36682218
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer.
Yang H; Kim VS; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen A; Tomlinson G; Alibhai SMH
J Geriatr Oncol; 2023 Jan; 14(1):101395. PubMed ID: 36988103
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
[TBL] [Abstract][Full Text] [Related]
6. Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.
Salem S; Komisarenko M; Timilshina N; Martin L; Grewal R; Alibhai S; Finelli A
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):601-608. PubMed ID: 28395931
[TBL] [Abstract][Full Text] [Related]
7. Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of
Karimzadeh A; Soeiro P; Feuerecker B; Hecker CS; Knorr K; Heck MM; Tauber R; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Nov; 64(11):1765-1771. PubMed ID: 37678925
[TBL] [Abstract][Full Text] [Related]
8. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
Oyenuga M; Halabi S; Oyenuga A; McSweeney S; Morgans AK; Ryan CJ; Prizment A
Prostate; 2023 May; 83(7):688-694. PubMed ID: 36842158
[TBL] [Abstract][Full Text] [Related]
9. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data.
Holm M; Doveson S; Lindqvist O; Wennman-Larsen A; Fransson P
BMC Palliat Care; 2018 Dec; 17(1):126. PubMed ID: 30509249
[TBL] [Abstract][Full Text] [Related]
11. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
12. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
Reichard CA; Gregg JR; Achim MF; Aparicio AM; Pettaway CA; Pisters LL; Ward JF; Davis JW; Chapin BF
Eur Urol; 2018 Aug; 74(2):140-143. PubMed ID: 29656854
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ; Oving IM; Wyndaele DNJ; van Basten JP; Terheggen F; van de Luijtgaarden ACM; Oyen WJG; van Schelven WD; van den Berkmortel F; Mehra N; Janssen MJR; Prins JB; Gerritsen WR; Custers JAE; van Oort IM
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):142-150. PubMed ID: 35804188
[TBL] [Abstract][Full Text] [Related]
14. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; Coenen JLLM; van Moorselaar RJA; van den Berg P; Geenen MM; Mehra N; Hendriks MP; Lampe MI; van de Luijtgaarden ACM; Peters FPJ; Roeleveld TA; Smilde TJ; de Wit R; van Oort IM; Gerritsen WR; Uyl-de Groot CA
Clin Genitourin Cancer; 2020 Jun; 18(3):e233-e253. PubMed ID: 31883940
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
Saad F; de Bono J; Barthélémy P; Dorff T; Mehra N; Scagliotti G; Stirling A; Machiels JP; Renard V; Maruzzo M; Higano CS; Gurney H; Healy C; Bhattacharyya H; Arondekar B; Niyazov A; Fizazi K
Eur Urol; 2023 Apr; 83(4):352-360. PubMed ID: 35750582
[TBL] [Abstract][Full Text] [Related]
16. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer-A qualitative study.
Rönningås U; Holm M; Doveson S; Fransson P; Beckman L; Wennman-Larsen A
Eur J Cancer Care (Engl); 2022 Jul; 31(4):e13592. PubMed ID: 35411645
[TBL] [Abstract][Full Text] [Related]
17. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M; Sormunen J; Luukkaala T; Marttila T; McDermott R; Joensuu T; Lehtinen I; Ginman C; Kellokumpu-Lehtinen PL
Acta Oncol; 2022 Aug; 61(8):963-971. PubMed ID: 35847998
[TBL] [Abstract][Full Text] [Related]
18. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
[TBL] [Abstract][Full Text] [Related]
19. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in men with metastatic castration-resistant prostate cancer.
Gee A; Challapalli A; Bahl A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]